Log In
BCIQ
Print this Print this
 

Veltassa, patiromer (RLY5016)

Also known as: formerly Patiromer FOS

  Manage Alerts
Collapse Summary General Information
Company Galenica Ltd.
DescriptionHigh-capacity oral potassium binder
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHyperkalemia
Indication DetailsTreat hyperkalemia; Treat hyperkalemia in chronic kidney disease (CKD) patients; Treat hyperkalemia in patients with nephropathy due to Type II diabetes and chronic kidney disease (CKD)
Regulatory Designation U.S. - Special Protocol Assessment (Treat hyperkalemia in chronic kidney disease (CKD) patients)
PartnerFresenius SE & Co. KGaA;
Galenica Ltd.;
Sanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$1,665.0M

$1,540.0M

$125.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today